Primary Pulmonary Hypertension
8
0
1
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
25.0%
2 terminated out of 8 trials
66.7%
-19.8% vs benchmark
25%
2 trials in Phase 3/4
100%
4 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder